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Abstract
Background: Innovative approaches are needed to support patients’ adherence to drug therapy. The Real Time
Medication Monitoring (RTMM) system offers real time monitoring of patients’ medication use combined with short
message service (SMS) reminders if patients forget to take their medication. This combination of monitoring and
tailored reminders provides opportunities to improve adherence. This article describes the design of an
intervention study aimed at evaluating the effect of RTMM on adherence to oral antidiabetics.
Methods/Design: Randomised Controlled Trial (RCT) with two intervention arms and one control arm involving
diabetes type 2 patients with suboptimal levels of adherence to oral antidiabetics (less than 80% based on
pharmacy refill data). Patients in the first intervention arm use RTMM including SMS reminders and a personal
webpage where they can monitor their medication use. Patients in the second intervention arm use RTMM
without SMS reminders or webpage access. Patients in the control arm are not exposed to any intervention.
Patients are randomly assigned to one of the three arms. The intervention lasts for six months. Pharmacy refill data
of all patients are available from 11 months before, until 11 months after the start of the intervention. Primary
outcome measure is adherence to oral antidiabetics calculated from: 1) data collected with RTMM, as a percentage
of medication taken as prescribed, and as percentage of medication taken within the correct time interval, 2) refill
data, taking the number of days for which oral antidiabetics are dispensed during the study period divided by the
total number of days of the study period. Differences in adherence between the intervention groups and control
group are studied using refill data. Differences in adherence between the two intervention groups are studied
using RTMM data.
Discussion: The intervention described in this article consists of providing RTMM to patients with suboptimal
adherence levels. This system combines real time monitoring of medication use with SMS reminders if medication
is forgotten. If RTMM proves to be effective, it can be considered for use in various patient populations to support
patients with their medication use and improve their adherence.
Trial registration: Netherlands Trial Register NTR1882
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Adherence can be defined as the extent to which a per-
son’s behaviour - taking medication and/or executing
lifestyle changes, corresponds with agreed recommenda-
tions from a health care provider [1]. Many patients,
especially patients with a chronic illness, experience dif-
ficulties in following treatment recommendations.
Adherence to long-term therapy for chronic illnesses in
developed countries averages only 50% [1]. As a result
of poor adherence, patients do not receive optimal bene-
fit from their drug therapy. Suboptimal treatment can
lead to increased use of health care services (acute care
and hospitalizations), reduction in patient’sq u a l i t yo f
life, and increased health care costs (drug costs and
medical costs) [1-5]. Thus, improving adherence receives
world-wide attention. In 2003, the World Health Orga-
nization emphasized that “increasing the effectiveness of
adherence interventions may have a far greater impact
on the health of the population than any improvement
in specific medical treatments” [1]. Many interventions
to improve patients’ adherence to medication have been
carried out in the last decades, but most of them did
not show significant effects on adherence. Even with the
most effective interventions, improvements in adherence
and treatment outcomes were generally small [6-9].
Evidently, there is a need for innovative approaches to
support patients in following prescribed therapy [6].
Most promising are interventions that are both simple
for the patient and relatively easy to implement in daily
clinical practice [8,10]. One such innovative approach is
the recently developed Real Time Medication Monitor-
ing (RTMM) system. This system is an innovative adap-
tation of the well-known Medication Event Monitoring
System (MEMS). MEMS uses an electronic medication
bottle with a microprocessor incorporated into the cap
that records the date and time the bottle is opened.
MEMS provides an objective and reliable measure of
adherence to prescribed medication [11,12] and it has
been used to measure medication adherence of various
patient populations, including those with asthma [13],
diabetes [14], schizophrenia [15] and heart failure [16].
Moreover, MEMS appears to improve adherence
slightly, especially when the system is used for a short
time [17]. The new RTMM system also uses an electro-
nic medication dispenser which monitors patients’ medi-
cation use but, as opposed to MEMS, it registers this
data in real time at a central server. This real time infor-
mation is directly available through the internet for
patients as well as for their care providers. Furthermore,
the RTMM system combines monitoring of medication
use with a reminder aspect. An explorative study in
which patients were reminded daily of their medication
intake through a short message service (SMS) showed
short-term improvement of adherence among diabetes
type 2 patients [18]. However, the effects diminished
over time. This might have been the result of the SMS
reminders becoming a routine, as in this study they
were sent before every intake, and were not triggered by
the actual medication use. As the RTMM system regis-
ters medication intake data in real time, it is possible to
remind patients only when necessary, that is when they
actually forget to take their medication. Patients who
take their medication in time do not receive SMS-alerts.
In this way habituation, and the possible loss of effec-
tiveness associated with it, can be averted. As such, the
RTMM system provides opportunities to improve
adherence to medication.
Interventions using reminders to improve adherence,
such as the one described in this article, are primarily
based on the principles of behavioural learning theory,
one of the five theoretical perspectives on adherence
outlined by Leventhal and Cameron [19]. According to
this theory, behaviour depends on stimuli or cues, either
internal (thoughts) or external (environmental cues),
which elicit certain behaviour. As such the desired beha-
viour can be learned and maintained by automation
after sufficient repetition. The intervention tested in this
study aims to modify the behaviour of non-adherent
patients by sending external stimuli, in this case SMS
reminders.
In addition to the simplicity for the patient and the
feasibility of implementation in busy daily practice,
interventions also need to be tailored to the patients’
reasons for not adhering to medication treatment. Here
two types of non-adherence can be distinguished: inten-
tional non-adherence where the patient deliberately
misses or alters the doses, and unintentional non-
adherence where the patient simply forgets to take the
medication. Interventions aimed at improving adherence
should address these two types separately [20-22].
Increasing one’s awareness of the benefits of the medi-
cation is unlikely to improve adherence in patients who
unintentionally fail to adhere to medication. Likewise,
reminding patients to take their medication will not be
helpful for patients who decide to miss or alter their
dosage on purpose. Although both types of non-
adherence are common, patients more often report unin-
tentional non-adherence [21,22]. RTMM can be
especially useful in improving adherence for these patients
who forget to take pills or are inaccurate in their timing.
A small pilot project reported patients’ positive experi-
ences with this new system [23]. However, the effects of
the system on adherence levels are yet to be investi-
gated. This study proposes a Randomised Controlled
Trial (RCT) to evaluate the effect of RTMM on medica-
tion adherence in patients with type 2 diabetes.
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increase. Adherence to oral antidiabetics ranges from 36%
to 93% [24]. Improving adherence in diabetes patients
leads to better glycaemic control and could in the long-
term reduce the incidence of micro- and macrovascular
complications associated with diabetes [25,26]. Further-
more, an increase in adherence in diabetes patients can
lead to a net reduction in health care costs [3].
The main objective of the intervention study described
in this article is to evaluate the effect of RTMM with
SMS reminders on the adherence to oral antidiabetic
medication of diabetes type 2 patients with suboptimal
levels of adherence. The central research question that
will be addressed in this study is: To what extent does
adherence to oral antidiabetic medication improve in
patients who use the RTMM system with SMS remin-
ders compared to 1) patients who use the RTMM sys-
tem without SMS reminders, and 2) patients who
receive usual care?
This article describes the design of this study and dis-
cusses the strengths and limitations of the study proto-
col. The results will be published in separate articles.
Methods/Design
Design
This study is a Randomised Controlled Trial (RCT) with
two intervention arms and one control arm involving
diabetes type 2 patients selected from 40 pharmacies
belonging to Mediq, a Dutch pharmacy chain. Patients
are randomly assigned by the research group to one of
the three groups. Patients are invited by their pharmacy
to participate in the study. Patients in the two interven-
tion groups use the RTMM system either with SMS
reminders (first intervention group) or without SMS
reminders (second intervention group) for a period of
six months. Patients in the control group are not
exposed to any intervention. Pre- and post-tests as well
as a follow-up test are performed. A flowchart of the
study is shown in Figure 1.
Ethical approval
The Medical Ethics Committee of the Utrecht Academic
Medical Centre approved the protocol (METC protocol
number 08-165/C). The anonymity of every patient is
guaranteed because all data are coded. Neither NIVEL,
nor the head office of Mediq, nor Evalan (the supplier
of the RTMM system) has access to information on
individual patients. Only the pharmacies are able to link
patient codes to individual patient information. Further-
more, all participants sign informed consent.
Participants
The inclusion criteria for participants in this study are:
1) Using oral antidiabetic medication for at least one
year.
There are three phases in pharmacotherapy: accep-
tance of the treatment plan, execution of the drug
regimen and discontinuation of dosing [27]. We
include patients who are beyond acceptance, the first
phase, thus patients who have used their medication
for at least one year. As such we deliberately exclude
patients who have not yet accepted their treatment
as these patients might be at increased risk of early
discontinuation of the therapy.
2) If insulin is used in combination with oral medi-
cation: using insulin for at least six months.
Patients who only recently initiated insulin therapy
along with their oral antidiabetics, within the past
six months, are excluded as these patients might still
be experimenting with the right combination of
insulin and oral antidiabetics.
3) Having a refill adherence of less than 80% calcu-
lated from pharmacy dispensing data from 11
months preceding the intervention.
One of the recommendations of Van Dulmen et al.
is to focus interventions on patients with suboptimal
levels of adherence [8]. The reason to select patients
who have an adherence level lower than 80% is that
these patients are more likely to benefit from the
proposed intervention. The 80% cut-off point is used
because missing 20% of the daily prescribed doses is
a relevant gap between prescribed and used medica-
tion. We estimated that this cut-off point should
provide sufficient eligible patients per pharmacy to
participate in the intervention. A lower cut-of point
would result in more pharmacies having to partici-
pate and this would lower the feasibility of the study.
4) Aged between 18 and 65 years.
Patients older than 65 years are excluded because
they frequently have a more complex clinical picture,
with several (chronic) diseases, more complications,
and more different medication to take.
5) Collected the last prescription for oral antidiabetics
within the two months prior to the intervention.
Patients should have collected their prescription
recently, that is within two months, to exclude
patients who might have stopped taking their medi-
cation completely.
6) Having knowledge of the Dutch language.
The questionnaires and the written patient informa-
tion about the RTMM system are in Dutch; there-
fore patients need to understand the language.
7) Using a mobile phone.
The intervention aims at improving adherence
through SMS reminders if necessary, thus patients
have to be in possession of a mobile phone.
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four are selected through an automated search in the
pharmacy data of 40 pharmacies. Patients who do not
meet criteria two and five are excluded on the basis of
manual evaluation of the refill data of the selected
patients. Patients are randomly assigned, per pharmacy,
by the research group to one of the three groups. The
age and gender distribution in the three groups as well
as the number of patients who use insulin beside oral
antidiabetics are evenly distributed in the three groups.
This type of randomization is known as restricted ran-
domization. The patient numbers, along with the group
assignments, are communicated to the pharmacies. The
last two criteria, having knowledge of the Dutch lan-
guage and possessing a mobile phone, are not available
f r o mt h ep h a r m a c yd a t aa n da r et h e r e f o r ea s k e dw h e n
the patient is invited to the pharmacy.
Intervention
The intervention consists of providing RTMM with SMS
reminders to diabetes type 2 patients who have subopti-
mal adherence levels to improve their adherence to oral
antidiabetic medication. Patients are invited by their
pharmacy to participate in the study. Pharmacists and/
Patient selection through manual evaluation 
of refill data
Control non-SMS   SMS
INTERVENTION
Randomization
of patients 
per pharmacy
INCLUSION PATIENTS (aim: 69 per group)  Data
Inclusion criteria 2 & 5
Patient selection through automated search 
in pharmacy data
Inclusion criteria 1,3 & 4
Pharmacies N=40
Questionnaire                                                
Pharmacy refill data
PRETEST
INTERVENTION
Duration: 6 months
Medication intake as 
registered by RTMM
Questionnaire                                                
Pharmacy refill data
Pharmacy refill data FOLLOW-UP
5 months after intervention
POSTTEST
Figure 1 Flowchart of the intervention study.
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project team about the procedure how to include
patients. The instruction covers how to approach
patients, provide the RTMM system and inform patients
about the intervention.
Patients in both intervention groups receive their
oral antidiabetics in the electronic medication dispen-
ser. During the six-month intervention period, the
actual medication use of patients is registered in real
time at a central database, hosted by the supplier of
the RTMM system, Evalan. The main researcher (Verv-
loet) receives an account with which she can log onto
this database at any time to retrieve the data. Patients
in the first intervention group, from here on called
SMS group, receive a SMS reminder if they do not
open their medication dispenser within an agreed time
period. These time periods are chosen by the patient
during the intake in the pharmacy. The number of
specified time periods is equal to the number of daily
doses prescribed by the general practitioner. One time
period is specified for a once daily dose regimen, two
time periods are specified for a twice-daily dose regi-
men and three time periods are specified for a three
times daily dose regimen. For every patient, the phar-
macy staff is provided with a form on which these
time periods and the patient’s mobile number can be
completed. This form is sent to Evalan, where the dis-
penser is programmed accordingly. These time periods
are also communicated to the main researcher. The
SMS reminder is sent at the end of this period when
the dispenser has not been opened. Patients, as well as
their pharmacists, receive an internet account through
which they can monitor their medication use. Patients
in the second intervention group, from here on called
non-SMS group, receive their medication in a similar
medication dispenser, but without SMS reminders and
an internet account. The medication use of these
patients is also registered in real time at a central data-
base. Patients in the third group, the control group,
receive usual care. They are not exposed to any inter-
vention and they are not approached during the six
months.
Measurements
The medication use of patients in both intervention
groups is registered by the RTMM system for a period
of six months. Pharmacy data are collected for all parti-
cipating patients over a total period of 22 months. This
comprises 11 months prior to the intervention, for a
pre-test, six months during the intervention, for a post-
test, and five months after the intervention, for a follow-
up test. Data include patient characteristics such as age
and gender, and the quantity and regimen information
of all dispensed medication.
Primary outcome measure is the adherence to oral
antidiabetic medication, which is calculated from data
collected through electronic monitoring (RTMM) and
pharmacy refill data.
1) Adherence calculated from data registered by the
RTMM-system is defined as:
a. the number of medication doses taken divided
by the number of prescribed doses;
b. the number of medication doses taken within
the correct time interval, the time period being
agreed with the patient, with a range of x hours
after this period divided by the number of pre-
scribed doses;
These outcome measures are used to study differences
in the level of adherence between the two intervention
groups during the intervention. In addition, the effect of
the SMS reminders on taking medication on time is stu-
died. The proportion of patients who need reminders is
studied as well as changes in this proportion over time.
Furthermore, by varying the cut-off points for adherence
we investigate the effects of this variation on the out-
come using sensitivity analysis.
2) Adherence as calculated from pharmacy refill data
is defined as the number of days for which the oral
antidiabetic medication is dispensed during the
study period divided by the total number of days of
the study period.
This outcome measure is used to study differences in
the level of adherence between the three groups before
and after the intervention. Moreover, it is used to study
whether the adherence of the two intervention groups
differs from the control group during the intervention.
Furthermore, two questionnaires, one pre-test and one
post-test, are completed by all participants. For compar-
ability, questions at post-test are mostly similar to those
at pre-test. Socio-demographic factors such as age, gen-
der, education level and ethnicity, are asked only in the
pre-test questionnaire. Both questionnaires contain
questions about factors that may be associated with
adherence, such as patients’ beliefs about their diabetes
medication and their illness perceptions. Questions
about patients’ experiences with RTMM are added to
the post-test questionnaire for patients in both interven-
tion groups.
Sample size calculation
Sample size calculations are based on the expected effect
of the intervention on the primary outcome which is the
adherence. However, as this is the first study on the
effects of RTMM on levels of adherence, there are no
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improving medication adherence have relatively small
effects. We, therefore, hypothesize that the difference in
adherence level between the SMS group and control
g r o u pa tt h ee n do ft h ei n t e r v e n t i o ni s1 0p e r c e n t .
Power analysis showed that, using a one-sided t-test
(alpha = 0.05) for a 10 percent difference (SD = 20),
with a power of 0.90, 69 patients are needed in
each arm.
Data analysis
Data are analysed based upon an intention-to-treat prin-
ciple [28]. All patients, regardless of whether they actu-
ally finish the intervention, are included in the analysis.
Descriptive analyses are obtained about the demographic
characteristics of patients and other control variables in
both the pre- and post-test in all three groups. Differ-
ences are tested using chi-square or t-tests. To test the
effect of the intervention a multilevel design is used,
since the data have a nested structure. Medication
events are clustered within patients, and patients are
clustered within pharmacies. The primary outcome, the
adherence, is the dependent variable. All independent
variables of importance, for example socio-demographic
factors and medication regimen, are included in the
model to adjust for these variables. Data are analysed
with Stata 10.0 for Windows and MLwiN 2.11 for multi-
level modelling.
Discussion
The intervention study described in this article is based
on the innovative Real Time Medication Monitoring
(RTMM) system. This system is the first to combine
real time monitoring patients’ medication use with send-
ing reminders through SMS only when medication is
actually forgotten. Reminding per SMS is a relatively
simple method with low intrusiveness [29]. As such,
RTMM appears to be a simple intervention for patients.
Haynes and colleagues concluded in their review that
for short-term treatments, quite simple interventions
increased adherence. For long-term treatments, only
some complex interventions led to improvements in
health outcomes [9]. However, complex interventions
are difficult to implement, time-consuming and very
labour-intensive. Simple interventions that are relatively
easy to implement in busy daily practice are most pro-
mising [8,10]. This conclusion was shared by a forum of
twenty internationally renowned experts in the field of
adherence [30]. Furthermore, the intervention is aimed
at patients with suboptimal levels of adherence. These
are the patients who could benefit most from interven-
tions aimed at improving adherence. However, the iden-
tification of these patients appears to be difficult [10].
We believe that through our selection criteria we will
capture a group of non-adherent diabetes type 2 patients.
However, it has yet to be proved that our criteria have
indeed selected a group of patients for whom an inter-
vention such as RTMM can be beneficial.
Strengths and limitations
A common critique of electronic medication monitoring
based on the time and date the medication dispenser is
opened, is that it cannot be confirmed that the medica-
tion is actually taken or that no more or no less than
the prescribed dose is taken. Only drug assays can
confirm ingestion. However, studies comparing the
sequence of medication events with projected and peri-
odically measured concentrations of the drug in plasma,
confirmed the validity of medication event monitors.
Mismatches between medication events and actual dos-
ing were too rare to create substantial differences
between projected and actual concentrations of the drug
in plasma [31-34]. Moreover, other methods to measure
adherence such as self-report and pill count tend to
overestimate adherence [35].
In addition, there is no consensual standard of ‘good
adherence’, because the level of adherence necessary to
achieve the desired effect varies between medications
and between and within patients [36]. We used the
cut-off point of 80% to label patients as adherent
(above 80%) or non-adherent (below 80%). Although
arbitrary, this cut-off point is more commonly used in
studies on adherence [2,37,38]. Furthermore, a lower
cut-off point would result in smaller numbers of
patients per pharmacy eligible to participate in the
intervention. More pharmacies would then be needed
to achieve desired patient numbers, lowering the feasi-
bility of the study.
Participation is restricted to pharmacies belonging to
one pharmacy chain. The success or failure of the inter-
vention could therefore be attributed to specific charac-
teristics of pharmacies within this chain. However, the
diversity of pharmacies within this chain is large and a
Dutch study has shown that being part of a chain does
not make a difference in the quality of care as perceived
by patients [39].
Theoretically, it is possible for the supplier of RTMM
(Evalan) to manipulate the data on medication use regis-
tered at the central database. However, both patients
and pharmacists have direct access to the data, they can
log onto this database at any given time to view the
patients’ medication use. Furthermore, the primary out-
come of this study which is adherence to oral antidia-
betics, is not only based on RTMM data, but also on
pharmacy refill data. Manipulation of the RTMM data
would result in a discrepancy between the RTMM data
and the refill data (internal inconsistency). Most impor-
tantly, the ultimate effect of the intervention is
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the control group no RTMM data is available.
The management of diabetes involves a healthy life-
style and long-term adherence to treatment, aimed at
preventing or delaying microvascular and macrovascular
complications. The main health outcome in diabetes
type 2 patients is to achieve and maintain good glycae-
mic control, that is an optimal blood glucose level
(HbA1c). One of the factors that contribute to achieving
glycaemic control is therapy with antidiabetic medica-
tion. Therefore, medication adherence is an intermediate
outcome measure. However, several studies have shown
that improvement of medication adherence leads to bet-
ter glycaemic control [26,40,41].
Conclusion
If this intervention, based on providing RTMM with
SMS reminders to diabetes type 2 patients with subopti-
mal adherence to achieve higher adherence levels,
proves to be effective it can be considered for use in
various patient populations to support patients in their
medication use and improve their adherence.
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